Percheron Therapeutics Ltd. (PERCF)
0.0024
0.00 (0.00%)
USD |
OTCM |
Oct 02, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 3.654M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -79.13% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 99.63% |
Profile
| Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the following segments: ATL1102 and HMBD-002. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The HMBD-002 segment refers to a recombinant, humanised monoclonal IgG4 antibody to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was founded on November 13, 2000 and is headquartered in Toorak, Australia. |
| URL | http://www.PercheronTx.com |
| Investor Relations URL | N/A |
| HQ State/Province | Victoria (VIC) |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Core |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the following segments: ATL1102 and HMBD-002. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The HMBD-002 segment refers to a recombinant, humanised monoclonal IgG4 antibody to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was founded on November 13, 2000 and is headquartered in Toorak, Australia. |
| URL | http://www.PercheronTx.com |
| Investor Relations URL | N/A |
| HQ State/Province | Victoria (VIC) |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Core |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |